Influenza, Human  >>  RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine) / Merck (MSD)
V419-006, NCT01340937 / 2011-004108-39: A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™

Completed
3
2808
NA
V419, PENTACEL™, Prevnar 13™, RotaTeq™, Recombivax HB vaccine
Merck Sharp & Dohme LLC, MCM Vaccines B.V.
Bacterial Infections, Virus Diseases
12/12
07/13
V419-007, NCT01341639 / 2010-021490-37: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months

Completed
3
1250
NA
V419, INFANRIX™ hexa, RotaTeq, Prevenar 13, ProQuad™
MCM Vaccines B.V., Merck Sharp & Dohme LLC
Bacterial Infections, Virus Diseases
03/13
03/13
V419-005, NCT01337167 / 2011-004095-10: Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™

Completed
3
1473
NA
V419, DAPTACEL™, PedvaxHIB™, Prevnar 13™, RotaTeq™, V260, PENTACEL™, Recombivax HB vaccine, ActHIB™
Merck Sharp & Dohme LLC, MCM Vaccines B.V.
Bacterial Infections, Virus Diseases
05/13
05/13

Download Options